NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10–300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid…
Clinical Trials (5)
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Started Jul 2025
10 enrolled
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
A Study to Learn About the Study Medicine - Precedex in Children From Japan.
Started Oct 2023
111 enrolled
Sedation
Precedex Special Investigation (in Pediatric Patients)
Started Jul 2019
111 enrolled
Sedation
Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Started Sep 2010
373 enrolled
Intensive Care Unit
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Started Oct 2009
89 enrolled
Endotracheal IntubationContinuous IV SedationICP Monitoring
Loss of Exclusivity
LOE Date
Jul 4, 2032
77 months away
Patent Expiry
Jul 4, 2032